Terapet closes seed financing round to advance the development of its medical device

The Swiss medtech startup Terapet raises CHF 1 million to support the development of its first full-scale prototype to be installed for clinical validation.

TERAPET is a medtech startups founded by two CERN physicists and a leading radio-oncologist from Geneva University Hospitals. The Geneva-based company develops and commercializes innovative solutions for a safer, more precise, and time-saving proton therapy for cancer treatment.

Today, the founders have announced the closing of a CHF 1 million seed financing round contributed by EFI (Efficient Frontier Investing), Nina Capital, FSI (Fongit Seed Invest), and three angel investors, with support of FONGIT. The seed financing will be, with CERN’s support, used to contribute to the development of the first full-scale prototype, ready for clinical validation at one of Terapet’s clinical partners, The Skandion Clinic in Sweden.

Terapet’s novel medical device will, for the first time, enable medical doctors to monitor the delivered proton dose inside the patients during cancer treatment: in-vivo, non-invasively, in 3D, and real-time. “With our solution, we will eliminate one of the biggest obstacles: ensuring that every patient receives the right dose, every time,” said Dr. Christina Vallgren, CEO of Terapet. “Additionally, our solution has the potential to further boost the growth of proton therapy in the near future, making it cheaper and available to a wider population.”

TERAPET has received financial support and coaching by Venture Kick and has recently been selected for the Venture Leaders Life Sciences 2020 program.